Arcadia Biosciences, Inc. (NASDAQ:RKDA – Get Free Report) was the recipient of a significant decrease in short interest in September. As of September 15th, there was short interest totaling 9,605 shares, a decrease of 48.8% from the August 31st total of 18,768 shares. Approximately 0.4% of the company’s stock are sold short. Based on an average daily volume of 54,883 shares, the days-to-cover ratio is presently 0.2 days.
Analysts Set New Price Targets
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Arcadia Biosciences in a report on Tuesday, September 22nd. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Arcadia Biosciences has a consensus rating of “Sell”.
Read Our Latest Analysis on RKDA
Arcadia Biosciences Trading Down 0.2%
Arcadia Biosciences (NASDAQ:RKDA – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The basic materials company reported ($2.09) EPS for the quarter, missing the consensus estimate of ($0.56) by ($1.53). Arcadia Biosciences had a negative return on equity of 183.50% and a negative net margin of 234.53%.The firm had revenue of $1.44 million for the quarter, compared to analyst estimates of $1.90 million.
About Arcadia Biosciences
Arcadia Biosciences, Inc is an agricultural biotechnology company focused on developing and commercializing plant-based products and crop technologies. The company has historically used advanced plant science and breeding techniques to improve the nutritional profile, sustainability, and commercial value of agricultural crops.
Its product portfolio has included GoodWheat, a wheat variety developed with reduced gluten and increased dietary fiber, and GoodHemp, a line of hemp products such as hemp seed, hemp protein, and hemp-derived ingredients.
See Also
- Five stocks we like better than Arcadia Biosciences
- Deutsche Bank Makes a Contrarian Call on Netflix—What Does It Mean for Investors?
- O’Reilly Automotive’s Stock Slump Hides a Stronger Business
- McDonald’s Stock Slump Makes Its AI Pricing Bet Even Riskier
- Broadcom’s AI Growth Story Faces a $161 Billion Anthropic Test
Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
